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Brain tumors constitute the most common intracranial tumor. Management of brain metastases has become increasingly complex
as patients with brain metastases are living longer and more treatment options develop. The goal of this paper is to review the role
of stereotactic radiosurgery (SRS), whole brain radiation therapy (WBRT), and surgery, in isolation and in combination, in the
contemporary treatment of brain metastases. Surgery and SRS both oﬀer management options that may help to optimize therapy
in selected patients. WBRT is another option but can lead to late toxicity and suboptimal local control in longer term survivors.
Improved prognostic indices will be critical for selecting the best therapies. Further prospective trials are necessary to continue to
elucidate factors that will help triage patients to the proper brain-directed therapy for their cancer.
1.Introduction
Brain metastases are the most common intracranial tumor,
arising in 10%–40% of all cancer patients [1, 2]a n d
accounting for up to 170,000 new cases per year in the
United States [3]. The observation of rising incidence
is most likely related to the aging population, improved
systemic treatment for the primary disease, and improved
imaging techniques [4]. As a result, brain metastases are
an increasing source of morbidity and mortality as well as
cognitive impairment at the time of cancer diagnosis [5, 6].
Cancers with a high incidence in the general population
(e.g., lung and breast) are the most frequently encountered
source of brain metastases, accounting for up to two thirds
of new cases [7]. Solid tumors constitute 95% of brain
metastases, while leptomeningeal involvement makes up the
remaining 5% [8–10]. Approximately 50%–60% of patients
with solid tumors present with multiple metastases, while
the remaining patients harbor a single mass [1, 11, 12].
The prognosis for patients with brain metastases from any
histology is poor overall, with a median survival of only 4–
7 months following treatment with WBRT alone [12–22].
For patients harboring a single, surgically amenable lesion,
resection followed by WBRT has been found to be favorable
to WBRT alone in two of three randomized controlled trials
[17, 19, 22]. The local control rates and overall survival
for patients with a single metastasis treated either with
surgical resection followed by WBRT or with stereotactic
radiosurgery (SRS) alone have been found to be similar
[18, 19, 22–28]. On the other hand, SRS may yield superior
local control rates for radioresistant brain metastases (e.g.,
from melanoma and renal cell) and provides the ability to
treat unresectable lesions. Recent series have documented
an improving survival among patients with brain metas-
tases, suggesting that improving systemic therapies may be
prolonging the lives of patients with brain metastases [29].
Such improvements imply that brain metastasis-directed
therapies may have increasing importance among longer-
term survivors. The purpose of this paper is to review
the role of SRS, WBRT, and surgery—either alone or2 International Journal of Surgical Oncology
in combination—in the contemporary treatment of brain
metastases.
2. SRS plus WBRT versusWBRT Alone
Several series have showed improvement in local control
with the addition of SRS to WBRT when compared to
WBRT alone. However, the detection of an overall survival
advantage has been elusive. This is likely because there are
speciﬁc populations that may beneﬁt from an SRS boost.
The ﬁrst prospective trial looking at the utility of an
SRS boost was published in 1999 by Kondziolka et al. This
single-institution RCT included patients with 2–4 metastases
measuring ≤2.5cm and a KPS ≥70 [27]. There were 14
patientsintheWBRTarmand13intheWBRTplusSRSarm.
The two groups were well matched with regard to gender,
age, number of lesions, KPS score, histology, and extent
of extracranial disease. Although the overall followup was
not reported, the study had the advantage of no crossover
between groups. The primary endpoint was local control
with secondary endpoints including time to progression
and median survival. The study was halted at the 60%
accrual point after interim evaluation revealed substantially
improved median time to progression (36 versus 6 months)
and local failure rate (8% versus 100%) for patients in
the WBRT plus SRS arm. Because of the small number of
patients, there was insuﬃcient power to assess diﬀerences in
median survival.
In 2004, Andrews et al. reported the results of the Ra-
diation Therapy Oncology Group (RTOG) multicenter trial
examining the use of WBRT versus WBRT plus SRS [30].
This was a randomized controlled study involving patients
with 1–3 brain metastases, a Karnofsky performance status
(KPS)of ≥70,andalesionsizeof<4cmforthelargestlesion.
Patient groups were matched for age, gender, KPS, histology,
and scores on minimental status exam (MMSE). They were
stratiﬁedbythenumberoflesionsandtheextentofextracra-
nial disease. The primary endpoint was median survival with
secondary endpoints of tumor control at 1 year, KPS and
MMSE at 6 months, and cause of death. There were 167
patients in the WBRT alone arm, 28 (17%) of whom crossed
over to receive SRS for salvage. The WBRT plus SRS arm
contained 164 patients, 31 (19%) of whom did not receive
the planned SRS boost. The trial demonstrated signiﬁcantly
improved survival for patients with single metastatic lesions,
better local control for patients with 1–3 lesions (P = 0.001),
andimprovedKPSforpatientswith1–3lesionsintheWBRT
plus SRS arm. There was no statistically signiﬁcant diﬀerence
between groups in incidence of neurologic death, MMSE at
6 months, toxicity, or median survival in patients with 2-
3 metastases. Criticisms of the trial include the absence of
imaging followup on 43% of the patients, a large crossover
rate between the arms, and inclusion of tumors >3cmwhich
are known to be less amenable to SRS.
Li et al. in 2000 reported their results of a three arm
prospective cohort study examining patients with either
small-cell or nonsmall-cell lung cancer with a single brain
metastasis measuring ≤4.5cm [31]. Seventy lung cancer
patients with newly diagnosed single brain metastasis were
treated with either WBRT alone (n = 29), or SRS alone (n =
23), or the combination of both (n = 18). Groups were well
matched with regard to gender, age, extent of extracranial
disease, histology, and KPS scores. Multiple endpoints,
including survival, freedom from local progression, freedom
from new brain metastasis, local control, KPS, and cause of
death, were measured and compared using univariate and
multivariate analyses. Analysis revealed improved median
survival (P<0.0001), local control (P = 0.004), and median
time to progression (P<0.0001) in the WBRT plus SRS arm.
However, the comparison between SRS alone and SRS plus
WBRT groups indicated that adding WBRT only improved
freedom from distant failure.
A large retrospective cohort trial performed by Sanghavi
et al. evaluated 502 patients from 10 institutions with brain
metastases from varying histologies [32]. They compared
this group to historical controls based on recursive par-
titioning analysis (RPA) of a database from RTOG trials
containing 1200 patients who received WBRT alone. The
patients were stratiﬁed by RPA class (number of brain mets,
presenceofsystemicdisease,andKPSscore)andweresimilar
ingender,age,andextentofextracranialdisease.Theauthors
observed statistically signiﬁcant improvements in survival
forpatientsreceivingWBRTplusSRSregardlessofRPAclass.
One criticism of the study is that the WBRT plus SRS group
had a larger percentage of radioresistant histologies and the
WBRT group had slightly lower initial KPS scores.
On the basis of the two randomized controlled trials
above, there is class I evidence that SRS plus WBRT yields
signiﬁcantly improved local tumor control rates compared
to WBRT alone in patients with 1–3 brain metastases.
Moreover, the study by Andrews et al. [30] suggests that
there are particular populations such as RPA class I patients
and those with single brain metastases that have an overall
survival beneﬁt with SRS boost. It is likely that the patients
who beneﬁt from an SRS boost are the ones that have an
improved life expectancy, as these patients will live long
enough to potentially experience the sequelae of local brain
failure.
3. SRSplus WBRT versusSRSAlone
T h el a t et o x i c i t i e so fW B R Th a v eb e e nw e l ld o c u m e n t e d .
Moreover,patientswithlongersurvivaltimesultimatelyhave
an increased chance of experiencing WBRT-related toxicity
[33]. As such, an approach of eliminating or delaying WBRT
in patients with brain metastases would potentially improve
cognitive outcomes in these patients. Multiple randomized
trials have now been published showing no decrease in
overall survival in patients in whom SRS alone was used to
treat ≤4 brain metastases.
A randomized controlled trial evaluating these two treat-
ments was performed by Aoyama et al. and published in
2006 [34]. Patients with up to four metastases ≤3cmanda
KPS of ≥70 were randomized to either SRS alone (n = 67)
or SRS plus WBRT (n = 65). The primary endpoint was
median survival while secondary endpoints included distant
failure, local control, and KPS scores at one year. Additional
secondaryendpoints included incidenceof neurologic death,International Journal of Surgical Oncology 3
MMSE scores, and adverse events. Those patients receiving
the combined treatment had the SRS dose reduced by 30%.
T h et w op a t i e n tg r o u p sw e r ew e l lm a t c h e dw i t hr e g a r d
to gender, age, number of lesions, histology, extent of
extracranial disease, and KPS scores. The follow-up period
was 21 months for the SRS arm and 31 months for the SRS
plusWBRTarm.Ofthe67patients intheSRSarm,11(16%)
required WBRT for salvage. In the SRS plus WBRT arm, 6
(9%) of patients did not receive SRS, 2 (3%) did not receive
WBRT, and 10 (15%) received additional SRS for salvage.
Analysis revealed no signiﬁcant diﬀerence between the two
groups with regard to median survival, local control rate,
KPS score, incidence of neurologic death, MMSE score, or
adverse events. However, the SRS arm had a signiﬁcantly
higher likelihood local and distant failure at one year requir-
ing salvage treatment with either additional SRS or WBRT.
InarecentphaseIIItrial,Kocheretal.comparedpatients
with 1–3 brain metastases, excluding small-cell lung cancer,
and stable extracranial disease that were randomized to
an observational cohort or WBRT cohort following initial
treatment with either SRS or surgery. Of the 199 patients
in the radiosurgery group, 100 patients were allocated to
observation,and99wereallocatedtoWBRT.Amongpatients
treated with surgery or SRS initially, there was no signiﬁcant
diﬀerence (P = 0.71) in the time to performance status
decline for the observation group (10 months) versus the
WBRT group (9.5 months). Similarly, overall survival times
were not signiﬁcantly diﬀerent (P = 0.89) between the
observation and WBRT arms (10.9 versus 10.7, resp.). They
concluded adjuvant WBRT reduces intracranial relapses and
neurologic deaths but fails to improve the duration of
functional independence and overall survival after SRS or
surgical treatment of cerebral metastases [35].
Chang et al. reported their results in 2009 of 58 patients
with 1–3 metastases who were randomized either to SRS
alone (n = 30) or SRS plus WBRT (n = 28) [36]. The
primary endpoint was cognitive status at 4 months, while
secondary endpoints were local control and overall survival.
Although the overall survival was higher in the SRS group
(15.2 versus 5.7 months), the 1-year local and distant failure
rates were higher. Six percent of the patients in the SRS plus
WBRTgrouprequiredsalvageSRS,while33%ofthepatients
in the SRS group required salvage resection and WBRT.
Verbal memory testing revealed signiﬁcantly less cognitive
decline in the SRS group.
There are multiple retrospective cohort studies (class
II evidence) that reveal similar survival results in patients
receiving SRS alone versus those receiving SRS plus WBRT
[37–44]. These studies contain conﬂicting evidence, how-
ever, regarding the risk of local recurrence in the patients
receiving SRS alone. As a result, while SRS alone is a rea-
sonable treatment option in patients with up to 4 brain
metastases, it should be followed by frequent MRI surveil-
lance for local and distant failure.
4. SRSAlone versusWBRT
At this time, there are no randomized trials directly com-
paring these two treatment modalities. In the three-armed
trial by Li et al. alluded to above, patients treated with
SRS alone demonstrated signiﬁcantly longer median survival
time (9.3 months) compared to those receiving WBRT
alone (5.7 months) [31]. In three other studies (class II),
there was a statistically signiﬁcant survival advantage for
patients receiving SRS alone for either single or multiple
tumors compared to those receiving WBRT [45–47]. One
class III study revealed similar outcomes for either treatment
modality [48], while a second showed a signiﬁcant survival
advantage for SRS alone [49]. On the basis of this data,
SRS alone is a reasonable treatment option for patients with
limited brain disease although concern about distant failure
necessitates frequent radiographic followup.
5. Surgery plus WBRT versus WBRT Alone
WBRT has been the mainstay treatment for brain metastases
for many years and continues to play a vital role in the
management of patients with this disease. However, com-
bining WBRT with surgical resection of symptomatic,
accessible lesions can improve survival and quality of life. In
a randomized trial (class I) performed by Patchell et al., sur-
gical resection followed by WBRT (n = 25) was compared
to WBRT alone (n = 23) for patients with a single metastatic
brain tumor [19]. The trial demonstrated signiﬁcantly
improved survival in the surgery plus WBRT arm (40 weeks)
compared to the WBRT alone group (15 weeks).
In a second randomized trial (class I) involving 63
patients by Vecht et al., the outcome after surgical excision of
asinglebrainmetastasisfollowedbyWBRTwascomparedto
that after WBRT alone [22]. WBRT was delivered in a novel
scheme of 2 fractions of 2Gy per day for a total of 40Gy.
Patients were stratiﬁed by primary site (lung cancer versus
nonlung cancer) and status of extracranial disease (progres-
sive versus stable). Survival and functionally independent
survival (FIS) were compared between the treatment arms.
The arm undergoing combined treatment had a longer
survival (P = 0.04) and longer FIS (P = 0.06) compared
with the group receiving radiotherapy alone. The ﬁndings
were most pronounced in patients with stable extracranial
disease (median survival, 12 versus 7mo; median FIS, 9
versus 4mo). Patients with progressive extracranial disease
had a median survival of 5 months and an FIS of 2.5 months
regardless of the treatment received.
The third, and largest, randomized trial (class I) eval-
uating these two treatment modalities was subsequently
performed by Mintz et al. in 1996 [17]. Forty-three patients
received radiation alone (3000cGy in 10 fractions), while
41 patients underwent surgery plus radiation. The median
survival for the WBRT alone group was 6.3 months com-
pared with 5.6 months for the surgery plus WBRT group
(P = 0.24). The majority of patients died within the ﬁrst year
(70% in the WBRT alone arm versus 88% in the surgery plus
WBRT arm). The authors concluded that the trial failed to
demonstratethattheadditionofsurgerytoradiationtherapy
improved outcome of patients with a single brain metastasis.
It should be noted that the study may have failed to show a
diﬀerence in treatment regimens, because the study included
patients with low KPS and extensive systemic disease.4 International Journal of Surgical Oncology
A recent, randomized trial by Kocher et al. compared
patients with up to 3 brain metastases and stable extracranial
disease that were randomized to an observational cohort
or WBRT cohort following initial treatment with either
SRS or surgery. There were 359 total patients in the study,
160 of whom received surgery. Although the study did not
directly compare patients receiving surgery plus WBRT to
patients receiving WBRT alone, they reported no advantage
to adjuvant WBRT after surgery compared to surgery or SRS
followed by observation in terms of the time to performance
status decline (9.5 versus 10.0 months, resp., P = 0.71) or
overall survival times (10.7 versus 10.9 months, resp., P =
0.89). They concluded adjuvant WBRT reduces intracranial
relapses and neurologic deaths but fails to improve the
duration of functional independence and overall survival
after SRS or surgical treatment of cerebral metastases [35].
Two of these three randomized controlled trials demon-
strate that the addition of resection to WBRT rather than
WBRT alone leads to improved survival and functional
status in patients with a single, surgically accessible brain
metastasis. A fourth study found no survival beneﬁt to add-
ing adjuvant WBRT to surgical resection. While much of this
data was acquired twenty years ago, it continues to be quite
relevant in the management brain metastases. It should be
recognized, however, that the majority of patients enrolled in
these trials were likely symptomatic or had larger metastases,
as these were the common presentation of brain metastases
in that era.
6. Surgery Plus WBRT versus Surgery Plus SRS
Atthistime,therearenoprospectivestudiescomparingthese
two treatment modalities. In a retrospective cohort study
by Serizawa et al. of patients with multiple metastases from
non-small cell lung cancer, 34 patients received resection
followed by WBRT while 62 underwent SRS [50]. Of the
latter group, 23 were treated with SRS either before or after
resection of a lesion >3cm. The patients who received SRS
demonstrated signiﬁcantly longer survival time (12.5 versus
6.6 months). The survival time of the subpopulation of
23 patients who underwent resection in combination with
SRS was not reported. The median time to distant brain
failure was 14 months in the SRS group and 17.6 months in
the group receiving WBRT although the diﬀerence was not
statistically signiﬁcant.
Given the paucity of studies comparing these two
treatment strategies, there is insuﬃcient evidence to justify
one over the other. However, the CALGB is in the process of
designing a prospective randomized trial that will randomize
patients with resected brain metastases to adjuvant WBRT
versus cavity-directed SRS plus SRS to any remaining metas-
tases. It is likely that this study will begin accrual in 2012.
7. Surgery Plus WBRT versus SRS Plus WBRT
Themajorissueunderlyingthesetwotechniquesisoptimiza-
tion of local control in cases where single modality therapy
is likely insuﬃcient. Larger brain metastases generally have
a higher local failure rate after surgery or SRS alone. As
such combined modality therapy oﬀers the ability to add a
second modality to improve local control. At this time, there
are no prospective studies comparing these two treatment
modalities although there are four retrospective studies.
Bindal et al. reported their results in 1996 comparing 62
patients with a single brain metastasis (<3cm)treatedwith
resection ± WBRT to 31 patients who underwent SRS ±
WBRT [51]. Patients were well matched with regard to
gender, age, KPS, extent of resection, and histology. WBRT
wasactuallycompletedby66%ofthepatientsintheﬁrstarm
and71%ofpatientsinthesecondarm.Theauthorsobserved
that those patients in the ﬁrst arm (resection plus WBRT)
demonstrated signiﬁcantly longer median time to recurrence
and median survival (16.4 versus 7.5 months) compared to
the second arm. In addition, those patients in the ﬁrst arm
hadasigniﬁcantly lowerrateofneurologic deathandadverse
events related to treatment.
O’Neill et al. reported their retrospective analysis of
97 patients with solitary brain metastases, 74 of whom
underwent resection, while the remaining patients received
radiosurgery [52]. The use of WBRT was similar between
the two groups (82% of surgical patients and 96% of
radiosurgery patients). While there was a trend toward
increased 1-year survival in the patients who underwent
resection (62% versus 56%), this did not reach statistical
signiﬁcance.However,therewasasigniﬁcantincreaseinlocal
tumor control for the patients receiving radiosurgery (100%
versus 42%) at a median followup of 20 months.
By contrast Sch¨ oggl et al. found improved results in
patients receiving radiosurgery rather than resection in a
retrospective, case-control study comparing these treatment
modalities [53]. They followed 133 patients whose treatment
for a single brain metastasis was either radiosurgery or sur-
gical resection. Only patients who received additional WBRT
were included in the study. Sixty-seven patients were treated
by radiosurgery and 66 patients were treated by resection.
Standard radiosurgical and WBRT doses were used. The
median survival for patients receiving radiosurgery was 12
months compared to 9 months for patients after resection,
ad i ﬀerence that did not reach statistical signiﬁcance. There
was,however,asigniﬁcantdiﬀerenceinlocalcontrolfavoring
the patients undergoing radiosurgery (95 versus 83%, P<
0.05).
Another recent, randomized trial by Kocher et al. com-
pared patients with up to 3 brain metastases and stable
extracranial disease that were randomized to an observa-
tional cohort or WBRT cohort following initial treatment
with either SRS or surgery. While the study did not directly
compare patients receiving patients receiving surgery plus
WBRT to patients receiving SRS plus WBRT, they found no
advantage to adding WBRT to either of the initial treatment
modalities in terms of the time to performance status decline
(10 versus 9.5 months, resp., P = 0.71) or overall survival
times (10.9 versus 10.7, resp., P = 0.89) [35].
While the ﬁrst two studies above reveal statistically
signiﬁcantly longer survival in patients receiving resection,
the third study demonstrated a trend towards longer survival
in those receiving SRS although it did not reach statisticalInternational Journal of Surgical Oncology 5
signiﬁcance. Further, Kocher’s study did not reveal an ad-
vantage with adjuvant WBRT for prolonged survival or
performance status after surgery or SRS. Both the Joint
Center for Radiation Therapy and MD Anderson attempted
randomized phase III trials comparing primary radiosurgery
to surgery in the 1990s. Neither of these studies were able
to accrue suﬃcient patients for analysis because of physician
bias. As a result, both strategies are reasonable in patients
with solid tumors <3 cm in diameter. However, surgery may
be more suitable for patients with symptomatic, accessible
lesions in order to palliate symptoms.
8. Surgery plus WBRT versus SRS Alone
There is one randomized controlled trial (class I) and two
retrospective cohort studies (class II) comparing these two
modalities.Muacevicetal.performedamulticenterprospec-
tive randomized trial involving 33 patients treated with
resectionfollowedbyWBRTand31patientstreatedwithSRS
alone [54] .A l lt u m o r sw e r e≤3cm in maximum diameter,
and all patients had a KPS ≥70. The primary endpoint of the
study was overall survival with secondary endpoints of local
control, toxicity, and quality-of-life measures. Treatment
results did not diﬀer in terms of survival (P = 0.8),
neurological death rates (P = 0.3), and freedom from
l o c a lr e c u r r e n c e( P = 0.06). Patients in the radiosurgery
group were more likely to demonstrate distant failure (P =
0.04). Radiosurgery was associated with a lower frequency
of adverse events (P<0.01). Improved scores for quality
of life measures were seen 6 weeks after radiosurgery (P<
0.05). It should be noted that quality of life measures were
no diﬀerent in the radiosurgery and surgery groups at 6
months after treatment. The authors concluded that the
main advantage of radiosurgery remains its less invasiveness
in terms of hospital stay, duration of treatment, and risk of
short-term toxicities.
T h es a m eg r o u pp r e v i o u s l yp e r f o r m e dar e t r o s p e c t i v e
cohort evaluation of 56 patients who underwent radio-
surgery alone versus 52 patients treated with resection
followed by WBRT [55]. The tumors were ≤3.5cm and the
two groups were well matched with regard to gender, age,
KPS scores, and extent of extracranial disease. The 1-year
survival rate was 53% (68 weeks) in the surgical group and
43%(35weeks)intheradiosurgicalgroup(P = 0.19).The1-
year rate of local control after surgery and radiosurgery were
75% and 83%, respectively (P = 0.49). The 1-year rate of
neurologicaldeathwas37%inthesurgicalgroupand39%in
the radiosurgical group (P = 0.8). A pretreatment KPS score
<70 was predictive of worsened survival. Periprocedural
morbidity and mortality rates were 7.7% and 1.6% in the
resection group and 8.9% and 1.2% in the radiosurgery
group.
Shinoura et al. performed a retrospective cohort evalua-
tion of 28 patients who underwent radiosurgery alone com-
pared to 35 patients treated with resection and radiotherapy
[56]. The two groups were well matched with regard to
gender, age, and histology but the extent of systemic disease
was not reported. Moreover, some of the patients received
local RT as opposed to WBRT, and the number of these
patients was not reported. Nonetheless, the authors reported
signiﬁcantlylongermediansurvival(34.4versus8.2months)
in the surgery plus RT arm. This arm also demonstrated
longer mean time to recurrence (25 versus 7.2 months)
during the follow-up period.
Given the inconclusive results of these studies, no deﬁni-
tiverecommendationscanbemaderegardingthesuperiority
of one of these treatment strategies over the other.
9. Surgery plus SRS versus SRS Alone
There are no studies comparing these two treatment options.
In general, surgery tends to be useful in larger lesions.
Multiple studies have reported good local control rates with
radiosurgical treatment of a resection cavity [34, 57–62].
Do et al. described their results with 30 patients with brain
metastases treated with resection followed by SRS or stereo-
tactic radiotherapy (4–6 fractions) to the resection cavity
[57]. Of the 30 patients, 4 (13.3%) developed recurrence in
the resection cavity, and 19 (63%) developed distant brain
failure. The actuarial 12-month survival rates were 82%
for local recurrence-free survival, 31% for freedom from
new distant brain metastases, 67% for neurologic deﬁcit-free
survival, and 51% for overall survival. Salvage WBRT was
performed in 14 (47%) of the 30 patients.
Jagannathan et al. reported their results with 47 patients
who underwent SRS to the postoperative resection cavity
following resection of a brain metastasis [59]. In addition to
the resection cavity, 34 patients (72%) underwent SRS to 116
intact metastases. The radiographic end point was deﬁned as
local tumor control. The mean volume of the treated cavity
was10.5cm3 (range1.75–35.45cm3),andthemeanmarginal
dose to the cavity was 19Gy. Clinical end points were deﬁned
as KPS and survival. The mean duration between resection
and SRS was 15 days. During a mean follow-up duration
of 14 months, local tumor control at the site of the surgical
cavity was achieved in 44 patients (94%). Recurrence in the
cavity was statistically related to the volume treated (P =
0.04). At the last followup evaluation, the mean KPS score
for the group was 78 (median 80, range 40–100). During the
follow-up period, 34 patients (72%) underwent additional
SRS for new metastases. At the time of last follow-up, 11
patients were alive and 36 patients had died (mean duration
until death 12 months). Patients with good control of their
primary tumor had improved survival compared to those
who did not (P = 0.004).
A 2009 study by Karlovits et al. involved a retrospective
review of 52 patients with 1–4 brain metastases treated
at their institution with SRS to a resection cavity [60]. A
single metastasis was resected in each patient. A median
dose of 1500cGy (range 800–1800cGy) was delivered to the
margin of the resection cavity. The median cavity volume
was 3.85cm3 (range 0.08–22cm3). With a median follow-up
durationof13months,themediansurvivalwas15.0months.
Four patients (7.7%) developed local recurrence within
the resection cavity. Twenty-three patients (44%) developed
distant brain recurrences at a median of 16 months after
resection. Sixteen (30.7%) received salvage WBRT. The
median time to WBRT delivery was 8.7 months (range6 International Journal of Surgical Oncology
2–43 months). Multivariate analysis revealed a signiﬁcantly
longer survival for patients with no extracranial disease on
presentation (P = 0.01) and solitary brain metastasis (P =
0.02). No factor (age, RPA class, tumor size or histological
type, extent of extracranial disease, extent of resection, or
SRS dose or volume) was related to the need for salvage
WBRT.
Hwang et al. analyzed their experience delivering SRS
to the tumor cavity following surgical resection of brain
metastases and compared their results to patients receiving
WBRT after surgical resection [58]. Twenty-ﬁve patients had
a metastatic lesion resected followed by adjuvant GKS to the
resection cavity. The median survival for patients receiving
SRS to the resection cavity was 15 months as compared to
6.8 months for those receiving WBRT (P = 0.08).
Jensen et al. recently described our experience at Wake
Forest University with 106 patients with no prior WBRT
who were treated using radiosurgery directed to the tumor
cavity and to any synchronous brain metastases detected at
the time of SRS planning [29]. A median dose of 17Gy
to the 50% isodose line was prescribed to the margin of
the resection cavity. Patients were followed up via serial
imaging, and new brain metastases were generally treated
using additional SRS, with salvage WBRT typically reserved
for local treatment failure at a resection cavity, numerous
failures, or failures occurring at short time intervals. SRS
was delivered to the resection cavity alone in 57.5% of
patients, whereas 24.5% of patients also received treatment
for 1 synchronous metastasis, 11.3% for 2 synchronous
metastases, and 6.6% for 3–10 additional lesions. Overall
survival at 1 year was 46.8%. The local tumor control
rate at 1 year was 80.3%. The disease control rate in
distant regions of the brain at 1 year was 35.4%, with a
median time of 6.9 months to distant failure. Thirty-nine
of 106 patients eventually required salvage WBRT, and the
median time to salvage WBRT was 12.6 months. Kaplan-
Meier estimates showed that the rate of requisite WBRT
at 1 year was 45.9%. Neurological cause-speciﬁc survival
at 1 year was 50.1%. Leptomeningeal failure occurred in 8
patients. Seven patients required repeat surgery. Multivariate
analysis revealed that preoperative tumor diameter >3cm
was predictive of treatment failure.
Given the absence of comparative studies regarding these
two treatment modalities, no recommendation can be made
regarding the superiority of one over the other. However,
SRS is inherently limited by the ability to control larger
lesions (>2cm) because of the inability to deliver adequate
dose. Surgery with such larger lesions provides the advantage
of potentially rendering the patient with only microscopic
residual disease. Adjuvant radiosurgery in this setting likely
has a better chance of controlling disease than it would with
an intact tumor.
10. Discussion
As evidence has become available that patients with brain
metastases are living longer than in the past [63, 64], the
management of patients with brain metastases has become
more complex. The complexity of this decision tree is under-
scored by the 2010 statement from the American College
of Radiology’s (ACR) Appropriateness Panel on single brain
metastasis that indicates that there is no clear consensus
regarding optimal or ideal treatment for these patients [65].
Table 1 demonstrates the major, prospective, randomized
trials that represent the basis for current management
strategies.
While local control of brain metastases continues to be
important,suchissuesasthelong-termtoxicityoftreatment,
and the optimal timing of WBRT are becoming equally
important. Moreover, the indications for radiosurgical man-
agement of brain metastases continues to evolve. At the
present time, the indications for radiosurgery include (1)
boost after WBRT for patients with <5 brain metastases,
(2) as monotherapy to avoid the cognitive toxicities of
WBRT in patients with <5 brain metastases, (3) as salvage
therapy after failure of previous WBRT, (4) radioresistant
brain metastases (e.g., renal cell carcinoma, melanoma,
and sarcoma), and (5) adjuvant therapy for a resected
radioresistant brain metastases (e.g., renal cell carcinoma,
melanoma, and sarcoma). For patients receiving SRS as a
boost after WBRT, this is generally reserved for patients
withpotentiallylongerlifeexpectancieswhoreceivedWBRT.
The previous randomized trial has suggested that patients
in the better prognostic group (e.g., 1 metastasis, or no
extracranial disease), tended to have improved survival with
radiosurgical boost. This is likely because patients with a
greater life expectancy have a longer potential time during
which to experience a local failure.
Twopublishedrandomizedtrialshavenowdemonstrated
that treating patients with <4 metastases with radiosurgery
alone not only does not lead to worsened overall survival,
but may also improve neurocognitive outcomes. These data
are somewhat controversial, however, given previous dogma
that distant or local brain failures are among the prominent
factors leading to neurocognitive decline in this patient
population. Furthermore, local failure after radiosurgery
appears to be a time-dependent phenomenon, and late
l o c a lf a i l u r e sa p p e a rt ob em o r ec o m m o ni np a t i e n t sw h o
receive radiosurgery alone as compared to WBRT with a
radiosurgical boost.
Perhaps more than ever, the use of prognostic indices
to triage patients with brain metastases into the proper
treatment algorithm is paramount. The RTOG published
a recursive partitioning analysis of patients with brain
metastases,separatingpatientsbasedon3prognosticgroups,
and basing these groupings on such variables as age, KPS,
and status of extracranial disease [26]. However, these data
were collected several decades ago, and the improvement in
systemic therapies and lead-time biases created by improved
imaging and surveillance may have caused this prognostic
index to become obsolete. Further eﬀorts to establish a
more modern prognostic index has given rise to the graded
prognostic assessment (GPA) based on histology-speciﬁc
prognostic factors [66]. Prognostic indices, while imperfect,
allow the treating physician to estimate the life expectancy
of the patient, and subsequently determine if WBRT can
be delayed or given upfront. Future prognostic indices may
ultimately incorporate failure patterns after SRS alone, inInternational Journal of Surgical Oncology 7
Table 1: Randomized Trials for Treatment of Brain Metastases.
Author Treatment Local Control (1yr) Distant Brain Failure (1yr) Overall Survival
Patchell [19] WBRT 48% 13% 9% (1yr)
Surgery plus WBRT 80% 20% 45%
Vecht [22] WBRT NA NA 23% (1yr)
Surgery plus WBRT NA NA 50%
Mintz [17] WBRT NA NA 17% (1yr)
Surgery plus WBRT NA NA 30%
Patchell et al. [18] Surgery 54% 37% 43wks
Surgery plus WBRT 90% 14% 48wks (median)
Andrews et al. [30] WBRT 71% 33% 23% (1yr)
WBRT plus SRS 82% 27% 29%
Kocher et al. [35] SRS 70% 44% 47% (1yr)
SRS plus WBRT 87% 28% 46%
Chang et al. [36] SRS 67% 55% 60% (1yr)
SRS plus WBRT 100% 27% 21%
Aoyama et al. [34] SRS 76% 63% 28% (1yr)
SRS plus WBRT 90% 42% 39%
order to help determine the patients who will fail outside of
the SRS treatment volume early on, and who may potentially
beneﬁt from upfront WBRT.
Perhaps one of the most important indications for SRS
is salvage of WBRT failures. The alternative to SRS in the
settingofWBRTfailureisrepeatWBRT.Thisoptionissignif-
icantly limited by toxicity and the ability to deliver suﬃcient
doses to the brain metastases. Several retrospective series
have documented median survival times of approximately 8
months after radiosurgical salvage of WBRT failures. Chao
et al. found that patients with brain metastases who recurred
afterWBRTandweretreatedwithsalvageSRShadgoodlocal
control and survival rates after SRS [67]. Those patients with
a longer time to failure after WBRT had signiﬁcantly longer
survival after SRS. Two other large retrospective studies have
demonstrated that SRS as a salvage treatment following in-
itial SRS can provide excellent local tumor control in pa-
tients with 4 or fewer metastases [68, 69].
SRS has also been widely used as an initial monotherapy
for radioresistant brain metastases such as renal cell carci-
noma, melanoma, and sarcoma. The seminal series dem-
onstrating suboptimal outcomes with WBRT alone for such
radioresistant tumors was published by investigators at MD
Anderson showing a rate of neurologic death as high as 76%
in patients with renal cell carcinoma receiving WBRT alone
[70]. On the other hand, several series have described a high
rate of durable location control and much lower rates of
neurologic death in series of patients receiving radiosurgical
management [71]. Clarke et al. have examined the outcomes
of patients with a single brain metastasis from radioresistant
histologies (renal cell carcinoma and melanoma) treated
with stereotactic radiosurgery (SRS) [72]. On the Basis of
their small retrospective series, they concluded SRS is a
safe and feasible strategy for treatment of patients with a
limited number of radioresistant brain metastasis. In those
few patients who received WBRT, local control, progression-
free survival, and overall survival were not signiﬁcantly im-
proved.
The role of surgical resection for brain metastases has
been well established. Large or symptomatic lesions will
commonly beneﬁt from the decompressive eﬀects of surgery.
In addition, SRS is inherently limited by the ability to deliver
suﬃcient tumoricidal doses to lesions greater than 2cm. In
these scenarios, surgery will provide improved local control
without the risk of radionecrosis. The surgical literature
should be interpreted in terms of the historical context that
most metastases detected during the era in which these
trials were conducted were either symptomatic or diagnosed
on CT. As such, there was probably a bias towards larger
and symptomatic lesions. Nonetheless, two randomized
controlled trials have demonstrated that the addition of
surgical resection to WBRT rather than WBRT alone leads
to improved survival and functional status in patients with
a single, surgically accessible brain metastasis [19, 22]. As a
result, it is general practice that all metastases larger than
3cm in surgically accessible regions should receive serious
consideration for resection.
The proper adjuvant therapy after surgical resection has
yet to be determined. While several randomized trials have
shown at least a local control beneﬁt to adjuvant WBRT
after resection of a brain metastasis, most have not shown
as u r v i v a la d v a n t a g e .H o w e v e r ,o b s e r v a t i o na f t e rs u r g i c a l
resection of a metastasis leads to a local failure rate of 50%
within the resection cavity. A number of recent series have
suggested that cavity-directed SRS as adjuvant therapy after
surgery is a viable option. This technique allows for the delay
or elimination of WBRT in most patients, while potentially
delaying or even avoiding the toxicities of WBRT. The com-
bined literature suggests a local control rate of approximately
80% at 1 year with cavity-directed SRS [29]. Improved
imaging techniques allow for detection and treatment of
synchronous brain metastases detected at time of SRS [73].8 International Journal of Surgical Oncology
In conclusion, management of brain metastases contin-
uestoevolveovertimeOnthebasisofimprovingsurvivalsof
patients and improving methods of prognostication. Surgery
and radiosurgery both oﬀer management options that may
help to optimize therapy in selected patients. WBRT is
another option but can lead to late toxicity and suboptimal
local control in longer term survivors. Further prospective
trials are necessary to continue to elucidate factors that will
help triage patients to the proper brain-directed therapy for
their cancer.
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